no but most clinical trials don’t meet starting aims. To be saying boom based on a trial is ambitious.
no a company needs to keep its focus on its primary business. This side game will cost money. Where is it coming from? That money and Human Resources takes away from primary objectives like Malta.
dont have a crystal ball just playing the odds. When all the worlds scientists are focussing on this problem why would mxc be likely to succeed when others fail.
added to that mxc track record of delivering on anything is not great
Ann: Phase II Clinical Trial on Patients Diagnosed with COVID-19, page-18
-
- There are more pages in this discussion • 35 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RGT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $13.58M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2500 | 26.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.0¢ | 3022 | 4 |
View Market Depth
| Last trade - 16.12pm 28/06/2024 (20 minute delay) ? |
| RGT (ASX) Chart |
Day chart unavailable